Research findings indicate that a single dose of RJVA-001 produces long-lasting metabolic enhancements in a db/db mouse model of type 2 diabetes. This treatment results in minimal systemic GLP-1 exposure, offering a potential solution to the issues of effectiveness, compliance, and side effects commonly associated with existing GLP-1 therapies. This study highlights the promising outcomes of RJVA-001 in addressing the challenges faced by current diabetes medications.